Overview
Industry leading TCR pipeline targeting solid tumors
Cancer is a leading cause of death worldwide and is characterized by the uncontrolled growth of abnormal cells whose ability to evade the immune system is key. Adaptimmune’s affinity enhanced T-cell therapies work with the immune system to improve detection and targeting of cancer cells, resulting in the destruction of those cancer cells. We believe that the unique potential of immunotherapy will revolutionize the treatment of oncology in the future and Adaptimmune is at the forefront of immunotherapy development.
SPEAR® T-cell therapies targeting MAGE-A4, and AFP are progressing through clinical studies in multiple solid tumors. The clinical studies for SPEAR® T-cell therapies targeting MAGE-A10 have been closed.
Our Pipeline
Adaptimmune is developing an industry-leading T-cell therapy pipeline in solid tumors, and has a deep pipeline of identified and proprietary targets for further product development.
| Target | Trial | Indications | Phase 1 | Phase 2/3 |
|---|---|---|---|---|
| MAGE-A4 | SPEARHEAD‑1 (ADP‑A2M4) | Synovial Sarcoma MRCLS |
Phase 1 Phase complete
|
Phase 2/3 Phase in progress
|
| SURPASS (ADP‑A2M4CD8) | Multiple solid tumors** |
Phase 1 Phase in progress
|
Phase 2/3 Phase not started
|
|
| Phase 1 trial (ADP‑A2M4) | Multiple solid tumors** |
Phase 1 Phase in progress
|
Phase 2/3 Phase not started
|
|
| Radiation sub‑study* (ADP‑A2M4) | Multiple solid tumors** |
Phase 1 Phase in progress
|
Phase 2/3 Phase not started
|
|
| AFP | Phase 1 trial (ADP‑A2AFP) | Hepatocellular carcinoma |
Phase 1 Phase in progress
|
Phase 2/3 Phase not started
|
| MAGE-A10 | Phase 1 trial (ADP‑A2M10) | NSCLC Melanoma Bladder Head and Neck |
Phase 1 Phase in progress
|
Phase 2/3 Phase not started
|
*Site specific protocol amendment with MD Anderson Cancer Center
**Bladder, Melanoma, Head & Neck, Ovarian, NSCLC, Esophageal, Gastric, Synovial sarcoma, MRCLS
